Syros Pharmaceuticals (SYRS) Earning Somewhat Positive News Coverage, Study Finds

Media coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.6959548677027 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

Several equities analysts recently issued reports on the stock. JMP Securities raised shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a research report on Thursday, September 28th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Oppenheimer set a $28.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 8th. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Finally, Zacks Investment Research raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $22.23.

Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.14 during trading on Monday, reaching $10.51. 257,300 shares of the company’s stock traded hands, compared to its average volume of 252,833. The firm has a market cap of $276.38 and a PE ratio of -6.04. Syros Pharmaceuticals has a 52-week low of $6.30 and a 52-week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). sell-side analysts predict that Syros Pharmaceuticals will post -2.12 EPS for the current year.

In related news, insider Jeremy P. Springhorn purchased 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $9.08 per share, for a total transaction of $136,200.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Srinivas Akkaraju purchased 109,774 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were bought at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Syros Pharmaceuticals (SYRS) Earning Somewhat Positive News Coverage, Study Finds” was first published by BBNS and is owned by of BBNS. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-syros-pharmaceuticals-syrs-share-price/1818079.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Insider Buying and Selling by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.